Peptides for Psoriasis and Autoimmune Skin Conditions: What the Research Shows
Evidence-based guide to peptides that may help manage psoriasis and inflammatory skin conditions. Covers BPC-157, GHK-Cu, KPV, and multi-peptide blends like KLOW.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Log your BPC-157 protocol in PeptIQ
Turn this BPC-157 guide into a living protocol — doses, vials, and history in one place.
Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist
Understanding Psoriasis and Autoimmune Skin Inflammation
Psoriasis is an autoimmune condition where the immune system triggers rapid skin cell production, creating thick, scaly patches. The underlying driver is chronic inflammation—specifically, dysregulated immune signaling involving TNF-α, interleukins (IL-17, IL-23), and NF-κB pathways.
Traditional treatments (topical steroids, biologics, immunosuppressants) target these pathways directly. Peptides offer a different approach: supporting the body's natural repair mechanisms and modulating inflammation without broad immunosuppression.
Important: Peptides are not FDA-approved for psoriasis treatment. This guide reviews the research for educational purposes only. Always work with a dermatologist for psoriasis management.
Peptides with Anti-Inflammatory and Skin Repair Properties
BPC-157: The Anti-Inflammatory Workhorse
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice. While most research has focused on gut and tendon healing, its anti-inflammatory mechanisms are relevant to skin conditions.
How it may help psoriasis:
Reduces TNF-α and other pro-inflammatory cytokines
Promotes angiogenesis (new blood vessel formation) for tissue repair
Accelerates wound healing and epithelial regeneration
Modulates nitric oxide pathways
Research context: Animal studies show BPC-157 reduces inflammation in various models. Human skin-specific trials are lacking, but users anecdotally report improvement in inflammatory skin conditions.
Typical protocol:
Dose: 250–500 mcg subcutaneously daily
Duration: 4–8 weeks
Some users inject near affected areas; others use systemic dosing
GHK-Cu: Copper Peptide for Skin Regeneration
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide that declines with age. It's one of the most studied peptides for skin health.
Mechanisms relevant to psoriasis:
Reduces NF-κB activity (a key inflammatory pathway in psoriasis)
Decreases pro-inflammatory cytokines
Promotes collagen synthesis and skin remodeling
Activates wound healing gene expression
Anti-oxidant properties reduce oxidative stress in lesions
Research highlight: GHK-Cu has been shown to reset gene expression patterns associated with aging and inflammation. One study documented modulation of 4,000+ genes related to tissue repair.
Typical protocol:
Dose: 1–2 mg subcutaneously daily
Duration: 8–12 weeks for visible skin changes
Can also be used topically (0.5–1% in carrier solution)
KPV: The Targeted Anti-Inflammatory
KPV is a tripeptide (lysine-proline-valine) derived from alpha-MSH (alpha-melanocyte-stimulating hormone). It's specifically known for its anti-inflammatory properties targeting NF-κB.
Why it's relevant to psoriasis:
Directly inhibits NF-κB activation (central to psoriatic inflammation)
Reduces pro-inflammatory cytokine production
Used in inflammatory bowel disease research (similar immune dysregulation)
No melanin-related effects unlike full alpha-MSH
Research context: KPV has shown efficacy in reducing gut inflammation in colitis models. The NF-κB pathway it targets is the same pathway implicated in psoriatic lesion formation.
Typical protocol:
Dose: 100–500 mcg subcutaneously daily
Duration: 4–8 weeks
Often stacked with BPC-157 for synergistic effects
Thymosin Alpha-1: Immune Modulation
Thymosin Alpha-1 (Tα1) is a thymic peptide that modulates immune function rather than suppressing it broadly.
Reduces autoimmune overactivation without immunosuppression
Caution: If you're on biologics (Humira, Enbrel, etc.) or immunosuppressants, Thymosin Alpha-1 could theoretically interfere. Consult your dermatologist before combining.
Typical protocol:
Dose: 0.5–1.5 mg subcutaneously 2–3x/week
Often cycled: 4 weeks on, 2 weeks off
Multi-Peptide Blends: KLOW and GLOW
Pre-mixed peptide blends like KLOW combine BPC-157, TB-500, and GHK-Cu in a single vial. For psoriasis and tendonitis (as mentioned by ryochs in our Discord), this offers:
Vitamin D: Optimize levels (psoriasis has strong Vitamin D connection)
Omega-3s: High-dose fish oil (2–4g EPA/DHA)
Stress management: Psoriasis flares with cortisol
Topicals: Continue prescribed treatments
Frequently Asked Questions
Q: Can I use peptides while on biologics (Humira, Skyrizi, etc.)?
A: BPC-157 and GHK-Cu don't have known interactions with biologics. Avoid Thymosin Alpha-1 without consulting your dermatologist, as it modulates immune function in ways that could theoretically interact with immunomodulating drugs.
Q: Are peptides better injected near psoriatic lesions or systemically?
A: Both approaches have proponents. Systemic injection (abdomen, thigh) distributes peptides throughout the body. Local injection may provide higher concentration at the site but is less convenient for widespread psoriasis.
Q: How long until I see results?
A: Most users report 4–8 weeks for noticeable changes. Skin turnover takes time, and psoriatic plaques are thick—expect gradual improvement rather than rapid clearing.
Q: Will psoriasis return if I stop peptides?
A: Likely, yes. Psoriasis is a chronic autoimmune condition. Peptides may reduce symptoms while used but don't cure the underlying immune dysregulation.
Q: What about scalp psoriasis?
A: Same peptides apply. Some users combine systemic peptides with topical GHK-Cu applied directly to scalp lesions.
Key Takeaways
BPC-157 and GHK-Cu have the most relevant mechanisms for psoriasis—anti-inflammatory and tissue repair properties
KPV targets NF-κB specifically, which is central to psoriatic inflammation
Multi-peptide blends like KLOW offer convenience and multiple pathways
Expect adjunctive support, not a cure—peptides work best alongside other treatments
4–8 weeks minimum before assessing results
Document baseline and track progress systematically
---
This article is for educational purposes only and does not constitute medical advice. Psoriasis is a medical condition requiring professional management. Always consult a dermatologist before starting any new treatment.
---
Track your peptide protocols with PeptIQ — dosing calculators, injection tracking, and protocol management all in one place. Download the app →
